An Open-label, Phase 1 Study to Characterize the Effects of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) on the Pharmacokinetics of MK-8527 in Healthy Participants
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; MK-8527 (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 19 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 05 Mar 2025 Status changed from not yet recruiting to recruiting.
- 17 Feb 2025 New trial record